Histone deacetylase (HDAC) inhibitors have been shown to be potent inducers of growth
arrest, differentiation, and/or apoptotic cell death of transformed cells in vitro and in vivo. One …

Histone deacetylase inhibitors are potent inducers of growth arrest, differentiation, or
apoptotic cell death in a variety of transformed cells in culture and in tumor bearing animals …

Histone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer
agents. Several of these compounds are in clinical trials with significant activity against a …

Inhibitors of histone deacetylase (HDAC) have been shown to induce terminal differentiation
of human tumor cell lines and to have antitumor effects in vivo. We have prepared …

Histone deacetylase inhibitors (HDACi) are a promising new class of chemotherapeutic drug
currently in early phase clinical trials. A large number of structurally diverse HDACi have …

Epigenic modifications, mainly DNA methylation and acetylation, are recognized as the main
mechanisms contributing to the malignant phenotype. Acetylation and deacetylation are …

Transformed cells, characterised by inappropriate cell proliferation, do not necessarily lose
the capacity to undergo growth arrest under certain stimuli. DNA, genetic information, is …

Aberrant gene regulation plays an important role in tumor initiation and progression, and the
acetylation of histones is a well understood key component of gene regulation. Histone …

Transformed cells have escaped normal growth regulatory signals and may be blocked at
discrete states of differentiation prior to the stage of terminal cell division and/or apoptosis …

Histone deacetylase inhibitors (HDAC inhibitors) represent a novel class of antineoplastic
agents that act by promoting acetylation of histones, leading in turn to uncoiling of chromatin …